BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/7/2020 11:53:47 AM | Browse: 627 | Download: 811
 |
Received |
|
2020-02-01 07:58 |
|
Peer-Review Started |
|
2020-02-01 07:58 |
|
To Make the First Decision |
|
2020-02-26 11:22 |
|
Return for Revision |
|
2020-02-27 15:14 |
|
Revised |
|
2020-06-23 00:14 |
|
Second Decision |
|
2020-06-24 08:48 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2020-06-25 04:56 |
|
Articles in Press |
|
2020-06-25 04:56 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2020-07-05 04:30 |
|
Publish the Manuscript Online |
|
2020-07-07 11:53 |
| ISSN |
2308-3840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Review |
| Article Title |
Immunotherapy in hepatocellular carcinoma: Combination strategies
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Alexander Claudius Jordan and Jennifer Wu |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jennifer Wu, MD, Associate Professor, Division of Hematology and Oncology, Perlmutter Cancer Center, New York University Langone Medical Center, 550 1st Avenue, New York, NY 10016, United States. jennifer.wu@nyulangone.org |
| Key Words |
Hepatocellular carcinoma; Liver neoplasms; Antineoplastic agents; Immunological; Protein kinase inhibitors; Angiogenesis inhibitors |
| Core Tip |
Immunotherapy remains a viable option for the systemic treatment of patients with unresectable hepatocellular carcinoma, although nivolumab and pembrolizumab failed to meet their endpoints in phase III studies. Combining immunotherapy with other treatment modalities may improve treatment responses. Multiple clinical trials are evaluating the safety and efficacy of these new combination strategies, which involve pairing PD-1 or PD-L1 inhibitors with CTLA-4 inhibitors, or pairing checkpoint inhibitors with alternative agents or non-pharmacologic therapies. |
| Publish Date |
2020-07-07 11:53 |
| Citation |
Jordan AC, Wu J. Immunotherapy in hepatocellular carcinoma: Combination strategies. World J Meta-Anal 2020; 8(3): 190-209 |
| URL |
https://www.wjgnet.com/2308-3840/full/v8/i3/190.htm |
| DOI |
https://dx.doi.org/10.13105/wjma.v8.i3.190 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
